Search
Displaying 11–20 of 1059 results for “fc 26 ps4 coins Visit Buyfc26coins.com for latest FC 26 coins news..NH7v”
-
Foundation News
The free, online event at 7 p.m. ET on Tuesday, November 11, 2025, will feature presentations from patient advocate Jessie Wolinsky, retina specialist Sandeep Grover, MD, and clinical psychologist Ann Wagner, PhD, LP, ABPP.
-
Natural History Study Launches for LCA Caused by Specific Mutation in CEP290
Research NewsThe natural history study will be used to characterize the range of visual function in patients, to evaluate which visual tests may be the most useful for patients with this condition, and to determine the rate of change in visual function over a one-year period.
-
Foundation News
Social media campaign to encourage personal story sharing to spread awareness about blinding diseases and empower involvement with the Foundation Fighting Blindness.
-
Recording Available: Insights Forum | Friday, December 12, 2025
Foundation NewsThe Foundation Fighting Blindness is pleased to provide a recording and full transcript of the Insights Forum, our quarterly conference call providing updates to the blinding diseases community. The call took place on December 12, 2025.
-
Foundation News
The May 14 event will convene leaders across industries to raise funds that advance treatments and cures for blinding diseases.
-
Research News
The emerging treatment targets a specific mutation (c.2991+1655A>G in Intron 26) of the gene CEP290 which causes Leber congenital amaurosis 10 (LCA 10)
-
Information for Newly Diagnosed Patients and their Loved Ones
-
Research News
Investigational LUXTURNA has the potential to be both the first pharmacologic treatment for an inherited retinal disease (IRD) and the first gene therapy for a genetic disease in the United States
First adeno-associated viral (AAV) vector investigational candidate to reach this stage of FDA review
Investigational LUXTURNA clinical program includes up to four years of efficacy data, with observation ongoing
-
Foundation News
The four-year study will inform clinical trial design for emerging USH3 therapies.
-
Allergan and Editas Begin Recruiting for CRISPR/Cas9 Clinical Trial for LCA10
Research NewsThe trial will be the first for a CRISPR/Cas9 therapy administered inside the human body.
